What are the major opportunities in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market? What are the strategies for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

For detailed insights on the major opportunities and strategies in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market, Read More

How does the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market growth and SWOT analysis of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment industry, Read More

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Global Report 2026 Market Report Infographic Image

Published : April 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report 2026

Name: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Type (Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types), By Indication (Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis), By End-Users (Hospitals, Homecare, Specialty Clinics, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

• Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market size has reached to $13.29 billion in 2025

• Expected to grow to $45.09 billion in 2030 at a compound annual growth rate (CAGR) of 27.6%

• Growth Driver: Impact Of Chronic Disease Prevalence On The Growth Of The Market

• Market Trend: Innovative Oral Treatments Drive Growth In The Market

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.

The main types of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment are transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other types. Transthyretin stabilizers are drugs that prevent transthyretin protein misfolding, reducing amyloid deposits and slowing disease progression in ATTR-CM. The various clinical indications include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. The treatment is used by various end-users, including hospitals, home care, specialty clinics, and others.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Global Report 2026 Market Report bar graph

What Is The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size and Share 2026?

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size has grown exponentially in recent years. It will grow from $13.29 billion in 2025 to $17.03 billion in 2026 at a compound annual growth rate (CAGR) of 28.1%. The growth in the historic period can be attributed to improved disease awareness among cardiologists, increased diagnosis of rare cardiomyopathies, availability of targeted pharmacological therapies, expansion of specialty cardiac care centers, progress in genetic screening technologies.

What Is The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Forecast?

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size is expected to see exponential growth in the next few years. It will grow to $45.09 billion in 2030 at a compound annual growth rate (CAGR) of 27.6%. The growth in the forecast period can be attributed to expansion of precision medicine approaches, growing development of next-generation gene-silencing therapies, rising investments in rare disease drug pipelines, increasing patient access to advanced cardiac diagnostics, stronger focus on disease-modifying treatments. Major trends in the forecast period include increasing adoption of transthyretin stabilizer therapies, rising use of rnAI-based treatment approaches, growing focus on early diagnosis and disease monitoring, expansion of personalized treatment regimens, increased investment in rare cardiac disease research.

Book your 30 minutes free consultation with our research experts

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation

1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Transthyretin Stabilizers: Tafamidis, Diflunisal

2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen

3) By RNAi Therapy: Patisiran, Vutrisiran

4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

What Is The Driver Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

The rising prevalence of chronic diseases is expected to propel the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market going forward. Chronic diseases are long-lasting conditions that progress slowly and persist for a year or more, often requiring continuous medical care. The rising prevalence of chronic diseases is attributed to factors such as aging populations, sedentary lifestyles, unhealthy diets, increasing obesity rates, and exposure to environmental pollutants. Transthyretin amyloid cardiomyopathy treatment helps by stabilizing transthyretin, reducing amyloid buildup, improving heart function, and alleviating symptoms to better manage related chronic conditions. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency. in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the rising prevalence of chronic diseases is driving the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry.

Key Players In The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc

Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends and Insights

Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are focusing on developing innovative treatments for ATTR-CM, such as oral prescription medication to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medication refers to drugs prescribed by a healthcare provider that are taken by mouth, typically in the form of tablets, capsules, or liquid solutions. For instance, in November 2024, BridgeBio Pharma Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration for Attruby (acoramidis) for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have shown that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

In March 2024, Bayer AG, a Germany-based pharmaceutical company, acquired exclusive European marketing rights for acoramidis from BridgeBio Pharma for up to $310 million. With this acquisition, Bayer aims to leverage its established cardiovascular commercial infrastructure to bring a new oral therapy for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) to the European market, thereby expanding its presence in rare cardiovascular disease therapeutics. BridgeBio is a US-based biopharmaceutical company focused on genetic and rare diseases, developing acoramidis as a highly potent, orally administered small-molecule transthyretin (TTR) stabilizer intended to treat ATTR-CM.

Regional Outlook

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report 2026?

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (attr-cm) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$17.03 billion
Revenue Forecast In 2035	$45.09 billion
Growth Rate	CAGR of 28.1% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Type, Indication, End-Users
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Transthyretin Stabilizer Therapies

4.2.2 Rising Use Of Rnai-Based Treatment Approaches

4.2.3 Growing Focus On Early Diagnosis And Disease Monitoring

4.2.4 Expansion Of Personalized Treatment Regimens

4.2.5 Increased Investment In Rare Cardiac Disease Research

5. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Cardiology Centers

5.4 Academic Medical Centers

5.5 Homecare Providers

6. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size, Comparisons And Growth Rate Analysis

7.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation

9.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types

9.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis

9.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Homecare, Specialty Clinics, Other End Users

9.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Tafamidis, Diflunisal

9.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Aspirin, Ibuprofen

9.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Patisiran, Vutrisiran

9.7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies

10. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regional And Country Analysis

10.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

11.1. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

12.1. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

13.1. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

14.1. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

14.2. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

15.1. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

16.1. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

17.1. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

17.2. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

18.1. Taiwan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

18.2. Taiwan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

19.1. South East Asia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

19.2. South East Asia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

20.1. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

20.2. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

21.1. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

22.1. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

23.1. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

24.1. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

25.1. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

26.1. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

26.2. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

27.1. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

28.1. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

28.2. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

29.1. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

29.2. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

30.1. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

30.2. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

31.1. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

31.2. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

32.1. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

33.1. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

33.2. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

34.1. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview

34.2. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Segmentation By Indication, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regulatory and Investment Landscape

36. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Company Profiles

36.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Company Profiles

36.3.1. Alnylam Pharmaceuticals Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. BridgeBio Pharma Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Intellia Therapeutics Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.4. SOM Biotech S L Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Ionis Pharmaceuticals Inc Overview, Products and Services, Strategy and Financial Analysis

37. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Other Major And Innovative Companies

Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc

38. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

40. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market High Potential Countries, Segments and Strategies

40.1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2030 - Countries Offering Most New Opportunities

40.2 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2030 - Segments Offering Most New Opportunities

40.3 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Overview Of Key Products - Product Examples

Table 2: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Supply Chain Analysis

Table 4: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Raw Material Providers

Table 5: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Resource Providers

Table 6: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Manufacturers (Suppliers)

Table 7: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Distributors And Channel Partners

Table 8: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Key Technologies & Future Trends

Table 9: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Trends

Table 10: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major End Users

Table 11: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - TAM, US$ Billion, 2025

Table 15: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 97: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Company Scoring Matrix

Table 98: Alnylam Pharmaceuticals Inc Financial Performance

Table 99: BridgeBio Pharma Inc Financial Performance

Table 100: Intellia Therapeutics Inc Financial Performance

Table 101: SOM Biotech S L Financial Performance

Table 102: Ionis Pharmaceuticals Inc Financial Performance

Table 103: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Competitive Benchmarking (In USD Billions)

Table 104: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Competitive Dashboard

Table 105: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 106: Global, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030

Table 107: Global, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Table 108: Global, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), Segmentation By End-Users, 2025 – 2030

List Of Figures

Figure 1: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Overview Of Key Products - Product Examples

Figure 2: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Supply Chain Analysis

Figure 4: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Raw Material Providers

Figure 5: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Resource Providers

Figure 6: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Manufacturers (Suppliers)

Figure 7: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Distributors And Channel Partners

Figure 8: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Key Technologies & Future Trends

Figure 9: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major Trends

Figure 10: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Major End Users

Figure 11: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - TAM, US$ Billion, 2025

Figure 15: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 97: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Company Scoring Matrix

Figure 98: Alnylam Pharmaceuticals Inc Financial Performance

Figure 99: BridgeBio Pharma Inc Financial Performance

Figure 100: Intellia Therapeutics Inc Financial Performance

Figure 101: SOM Biotech S L Financial Performance

Figure 102: Ionis Pharmaceuticals Inc Financial Performance

Figure 103: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Competitive Benchmarking (In USD Billions)

Figure 104: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Competitive Dashboard

Figure 105: Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 106: Global, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030

Figure 107: Global, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030

Figure 108: Global, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size Gain ($ Billion), Segmentation By End-Users, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Hypertrophic Cardiomyopathy Treatment Market Report 2026 - Global Outlook – By Disease Type (Obstructive Hypertrophic Cardiomyopathy Treatment, Non-Obstructive Hypertrophic Cardiomyopathy Treatment), By Diagnosis (Chest ...

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2026 - Global Outlook – By Drug Type (Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types), By D...

Cardiometabolic Diseases Market Report 2026 - Global Outlook – By Type (Chronic Or Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity), By Treatment (ACE inhibitors, Diuretics, Glucophage), By Dosage (Table...

Ventricular Fibrillation Market Report 2026 - Global Outlook – By Treatment (Cardiopulmonary Resuscitation (CPR), Defibrillation, Medication, Catheter Ablation, Left Cardiac Sympathetic Denervation), By Diagnostic Techni...

Implantable Heart Pacemaker Market Report 2026 - Global Outlook – By Product Type (Single Chamber, Dual Chamber, Biventricular), By Application (Heart Block, Sick Sinus Syndrome, Other Applications), By End User (Hospita...

Heart Blocks Treatment Devices Market Report 2026 - Global Outlook – By Clinical Classification (First-Degree Heart Block, Second-Degree Heart Block, Third-Degree Heart Block), By Product (Transcutaneous Pacing (TCP), Pa...

Atrophic Glossitis Treatment Market Report 2026 - Global Outlook – By Treatment Type (Medications, Topical Treatments, Nutritional Supplements, Oral Care Products), By Symptoms (Inflammation, Discoloration, Itching, Burn...

Frequently Asked Questions

How big is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?

The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market was valued at $13.29 billion in 2025, increased to $17.03 billion in 2026, and is projected to reach $45.09 billion by 2030.

What is the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market growth?

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market is expected to grow at a CAGR of 27.6% from 2026 to 2035 to reach $45.09 billion by 2035.

Who are the key players in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

Some Key Players in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market Include, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc .

What is the anticipated growth trend for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

Major trend in this market includes: Innovative Oral Treatments Drive Growth In The Market. For further insights on this market. request a sample here

Which region has the most growth potential in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.